Editorial Staff

  • Executive Editor/VP-Special Projects:
    Jeff Hall
  • Senior Editor
    Brian McCurdy
  • Circulation and Subscriptions
    Bonnie Shannon
  • Art Director:
    Alana Balboni
  • Editorial Correspondence

  • Jeff Hall, Executive Editor/VP-Special Projects, Podiatry Today
  • HMP Communications, 83 General Warren Blvd
    Suite 100, Malvern PA 19355
  • Telephone: (800) 237-7285, ext. 214
    Fax: (610) 560-0501
  • Email: jhall@hmpcommunications.com
  • June 2008 | Volume 21 - Issue 6
    By Lowell Weil, Jr., DPM, MBA
    10,556 reads | 0 comments | 09/03/08
    When musculoskeletal extracorporeal shockwave therapy (ESWT) was first introduced in the United States with the first FDA approval in 2000, there was a great deal of controversy and posturing among manufacturers of ESWT technologies. Each company was determined to create an exclusive market for their product at the expense of the competition. One of the most common targets for criticism was the level of energy of the technology. Based on industry biases, high-energy ESWT was considered the most effective for the musculoskeletal system. Those devices that failed to reach high energy we... continue reading
    By M. Joel Morse, DPM
    4,951 reads | 0 comments | 09/03/08